Back to watching closely list!
$Bionomics(BNOX.US$ The Company has no outstanding debt, convertible securities, or warrants.
Continued strengthening BNC210 intellectual property portfolio in the U.S. and abroad.
Future Anticipated Milestones for BNC210 Clinical Program
Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.
The Company plans to discuss a potential dose-ranging late-stage study of BNC210 in PTSD with the FDA; an update on the next steps is expected by the end of Q2'24.
The Company is exploring the submission of a request for Breakthrough Therapy designation in PTSD in Q2'24.
Continued strengthening BNC210 intellectual property portfolio in the U.S. and abroad.
Future Anticipated Milestones for BNC210 Clinical Program
Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.
The Company plans to discuss a potential dose-ranging late-stage study of BNC210 in PTSD with the FDA; an update on the next steps is expected by the end of Q2'24.
The Company is exploring the submission of a request for Breakthrough Therapy designation in PTSD in Q2'24.
Leveraging the inbound demand, the Company is looking to secure a strategic partnership for BNC210. Several Companies have expressed interest.![]()
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Newbee4 : ty
TrytosaveabitOP Newbee4: You’re very welcome Darlin! GL today
Newbee4 TrytosaveabitOP: you too
Benhardman : You still holding?
TrytosaveabitOP Benhardman: Sold yesterday and looking to buy back in soon! GL